Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been given a consensus rating of "Buy" by the eight research firms that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.33.

Several research analysts recently commented on ZURA shares. Oppenheimer reduced their price objective on Zura Bio from $19.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, May 9th. Guggenheim reissued a "buy" rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, March 26th. Chardan Capital dropped their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, March 26th. Finally, HC Wainwright reiterated a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd.

Zura Bio Stock Performance

Shares of NASDAQ ZURA opened at $1.14 on Wednesday. The business's 50 day moving average price is $1.21 and its 200-day moving average price is $1.58. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $5.07. The company has a market cap of $77.95 million, a price-to-earnings ratio of -1.63 and a beta of -0.12.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). Sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ZURA. JPMorgan Chase & Co. grew its position in shares of Zura Bio by 12,060.8% in the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock valued at $6,583,000 after purchasing an additional 2,611,532 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in Zura Bio by 34.9% in the first quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock valued at $3,614,000 after acquiring an additional 723,933 shares during the last quarter. Allostery Investments LP grew its position in Zura Bio by 44.2% during the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock valued at $3,005,000 after acquiring an additional 714,258 shares during the period. Millennium Management LLC grew its position in Zura Bio by 1,499.0% during the fourth quarter. Millennium Management LLC now owns 701,278 shares of the company's stock valued at $1,753,000 after acquiring an additional 657,420 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Zura Bio during the fourth quarter worth about $750,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.